Amphista Therapeutics, a global leader in the discovery and development of next generation targeted protein degradation (TPD) therapeutics, May 4th announced a strategic collaboration...
SK bioscienceSK bioscience and GSK announced submission of a biologics license application for SKYCovione™ a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s pandemic...
Tirzepatide achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli Lilly and Company's SURMOUNT-1 clinical trial,...
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced positive preliminary Phase 1 data from independent dose finding...
New research has shown that a longer interval between primary COVID-19 vaccine doses can boost antibody production up to nine-fold. The study currently being presented at...
Roche announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as...